Heart transplant drug shows promise in preventing vessel damage
NCT ID NCT03537742
First seen Apr 19, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This study tested a drug called alirocumab in 114 heart transplant recipients to see if it could slow or prevent damage to the blood vessels of the new heart. The drug works by lowering cholesterol and other fats in the blood. The main goal was to measure changes in plaque buildup in the heart's arteries one year after starting the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.